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Abstract Recently, tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL/Apo2L) has been shown
to be a potential candidate for cancer therapy. TRAIL
induces apoptosis in various cancer cells but not in normal
tissues. Here we show that HCT116 and SW480 cells with a
deficient mitochondrial apoptotic pathway were resistant to
TRAIL-induced apoptosis, whereas HCT116 and SW480
cells with a functional mitochondrial apoptotic pathway
underwent apoptosis upon exposure to TRAIL. Surpris-
ingly, TRAIL induced phenotypic changes in cells with a
dysfunctional mitochondrial apoptotic pathway, including
membrane blebbing and a transient loss of adhesion
properties to the substratum. Accordingly, TRAIL stimu-
lated the ability of these cells to migrate. This behavior was
the consequence of a transient TRAIL-induced ROCK1
cleavage. In addition, we report that Bax-deficient HCT116
cells exposed to TRAIL for a prolonged period lost their
sensitivity to TRAIL as a result of downregulation of
TRAIL receptor expression, and became resistant to com-
bination of TRAIL and other drugs such as MG-132 and
bortezomib. These findings may have important conse-
quences for TRAIL anti-cancer therapy.
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Abbreviations
TRAIL Tumor necrosis factor (TNF)-related
apoptosis-inducing ligand
TNFR1 Tumor necrosis factor receptor-1
DISC Death inducing signaling complex
TRAIL-R1 TRAIL receptor-1
TRAIL-R2 TRAIL receptor-2
MLC Myosin light chain
ROCK1 Rho-associated, coiled-coil containing
protein kinase 1
IAPs Inhibitors of apoptosis
XIAP X-linked inhibitor of apoptosis
Introduction
Tumor necrosis factor (TNF)-related apoptosis inducing
ligand (TRAIL) is a type 2 transmembrane protein whose
extracellular domain shows homology with the extracel-
lular domain of Fas ligand and TNF-a [1, 2]. TRAIL is
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normally expressed in the immune system and plays a crit-
ical role in antitumor immunity. TRAIL binds its receptors
(DR4, also called TRAIL-R1 or DR5, also called TRAIL-
R2), and triggers apoptosis via the extrinsic pathway. TRAIL
receptors belong to the family of death receptors, which
includes TNFR1 and Fas (Apo1, CD95) receptors [3–7].
These receptors display a death domain in their intracellular
region. When bound to their ligands, they oligomerize and
recruit the cytosolic protein FADD, which in turn recruits
and activates caspase-8 [8, 9]. This expanding complex is
called the death inducing signaling complex (DISC) [10].
Caspase-8 in turn cleaves and activates executioner caspases
leading to apoptosis. In many cell types, the extrinsic path-
way is linked to the intrinsic mitochondrial pathway by tBid.
tBid, which is generated by the cleavage of Bid by caspase-8,
activates apoptosis by recruiting Bax in the mitochondrial
outer membrane [11]. This leads to permeabilization of the
outer mitochondrial membrane, cytochrome c release, cas-
pase-9 activation and ultimately to activation of executioner
caspases and cell death.
Although TRAIL preferentially induces apoptosis in
cancer cells, it also engages non-apoptotic signalling
pathways leading to activation of pro-survival molecules,
such as protein kinase C, phosphatidyl inositol 3 kinase
(PI3K), Akt, nuclear factor kappaB (NF-kappaB) and
mitogen-activated protein kinases [12–19]. These pathways
stimulate transcription of genes encoding anti-apoptotic,
angiogenic, mitogenic and cell migration-stimulating fac-
tors, raising the possibility of unwanted effects of TRAIL
in cancer therapy.
Resistance of cancers to TRAIL is one of the major
obstacles in TRAIL therapy. There are several causes for
TRAIL resistance including the loss of expression of
TRAIL-R1 and TRAIL-R2 on the plasma membrane,
increased level of TRAIL-R3, TRAIL-R4, c-FLIP, Bcl-2,
Bcl-xL, and loss of caspase-8 and -10 due to mutations
[20–22]. Members of the inhibitors of apoptosis (IAPs) are
reported to block the activity of caspase-9, -3 and -7 and
high expression of XIAP, one of the IAP family members,
has been shown to contribute to TRAIL resistance in a
number of tumor cell lines [23]. While exploring the
mechanisms of Bax activation induced by TRAIL, we
observed an unexpected behavior of Bax-/- HCT116
human colon cancer cells. Upon TRAIL treatment,
Bax-/- cells displayed robust membrane blebbing, and
detached from the culture dish similar to Bax-/? cells,
however, the Bax-/- cells re-adhered to the culture dish
after several hours and continued to proliferate. We have
found that blebbing of Bax-/- cells occurs through cas-
pase-3 mediated cleavage of ROCK1, a kinase important in
cell membrane blebbing and motility. In vitro, TRAIL
enhanced migration of Bax-/- cells. Moreover, a 24 h
exposure of HCT116 Bax-/- cells to TRAIL conferred
resistance to drug-mediated (such as MG-132 and bort-
ezomib) sensitization of these cells to TRAIL-induced
apoptosis. Cell detachment from the primary tumor is the
first of a series of events required for metastasis. Our
results raise the possibility that, in vivo, TRAIL anti-cancer
therapy may facilitate migration of tumor cells in which the
intrinsic mitochondrial pathway of apoptosis is impaired.
Materials and methods
Materials
Dulbecco’s Modified Eagle Medium (DMEM), L-gluta-
mine, fetal bovine serum (FBS), cell culture trypsin, MG-
132 and Y-27632 were from Sigma; cell culture plates
were from Nunc; Hoechst and Lipofectamine reagent were
from Life Technologies; Bortezomib was from ChemieTek
(USA); Hybond-P membranes were from GE Healthcare
Life sciences; Annexin V-FITC was from BD Biosciences;
The following antibodies were used. Bax (Neomarkers,
clone 2D2), Bcl-xL (Santa Cruz, S-18), cleaved caspase-3
and GAPDH (Cell Signaling), caspase-3 (Alexis), caspase-
8 (BD Pharmingen), PARP, ROCK1 (N-terminal), caspase-
7 and XIAP (BD Transduction Laboratories), actin and
ROCK1 [(C-terminal) (Sigma)], TRAIL-R1 and TRAIL-
R2 (Exbio) and ppMLC (Generously provided by James
Staddon, Eisai London Research Laboratories Ltd.,
London, UK).
Cell culture, transfections, and quantification
of blebbing and detachment
Cell lines were cultured in DMEM with 10 % FBS,
100 U/ml penicillin, 0.1 mg/ml streptomycin and 2 mM
glutamine, and maintained in 5 % CO2 at 37 C. HCT116
human colon cancer cell lines (HCT116 Bax-/? and
Bax-/-) that differ in the presence or absence of Bax were
kindly provided by Bert Vogelstein, Howard Hughes
Medical Institute. These isogenic cell lines were originally
generated from HCT116 colon cancer cells [24]. HCT116
Bax-/? cell lines over expressing Bcl-2 or Bcl-xL were
generated by retroviral transduction of HCT116 Bax-/?
cells followed by cell sorting using Coulter EPICS Elite
ESP, Beckman-Coulter-France, Villepinte, France [22].
In order to show that cleavage of ROCK1 is sufficient to
induce membrane blebbing, a plasmid encoding an active
form of ROCK1 [(ROCK1 (G1114opa); N-terminal domain
of ROCK1 cleaved by caspase-3; the cDNA was kindly
provided by Michael F. Olson, Beatson Institute for Cancer
Research, UK] was used to transiently transfect HCT116
Bax-/- cells. TRAIL resistant SW480 cells (ATCC) were
generated by transient transfection using a plasmid
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encoding anti-apoptotic protein Bcl-xL. For the downreg-
ulation of caspase-3, HCT116 Bax-/? and Bax-/- cells
were transfected with siRNA targeting caspase-3 [Mission
siRNA (ranking 1), SASI_Hs01_00139105] or universal
negative control (SIC001) (Sigma) using Microporator
MP100 (Digital Bio).
For blebbing and detachment analyses, cells were trea-
ted with 100 ng/ml of TRAIL or TRAIL (100 ng/ml) and
Y-27632 (10 lM) for 5 h to allow membrane blebbing and
detachment. Cells were then fixed with paraformaldehyde,
stained with Hoechst and observed using phase contrast
and fluorescence microscopy with a 639 objective (Zeiss
Axiovert 135). The morphology of blebbing cells could
easily be distinguished from that of non-blebbing adherent
cells. The blebbing cells are also distinct from refringent,
round cells that are undergoing mitosis. In order to com-
pare dead and living cells, HCT116 Bax-/? and Bax-/-
cells were left untreated or treated with 100 ng/ml of
TRAIL for 5 h. The cells were then stained with 5 ll/ml of
Annexin V-FITC and 1 mg/ml of Hoechst in 19 Binding
Buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2,
pH 7.4) for 5–10 min in the dark and imaged. The Hoechst
and annexin V stainings allowed us to differentiate
between blebbing cells undergoing apoptosis (they dis-
played a fragmented and/or condensed nucleus, and were
annexin V positive) and blebbing cells, which were resis-
tant to apoptosis (their nucleus was intact and these cells
were annexin V negative).
Combined TRAIL and proteasome inhibitor treatments,
and apoptosis quantification
HCT116 Bax-/- cells were categorized into the following
three groups: cells that had never been exposed to TRAIL
(naı¨ve cells); cells that had been pretreated with TRAIL for
24 h (pretreated cells); cells that received TRAIL for 24 h,
then were left untreated for 48 h before a second exposure
to TRAIL (sequentially treated cells). Each group of cells
was left untreated or treated with TRAIL (100 ng/ml), MG-
132 (10 lM), bortezomib (25 nM), TRAIL (100 ng/ml)
and MG-132 (10 lM) or TRAIL (100 ng/ml) and bort-
ezomib (25 nM). Cells were harvested after 5 h of treat-
ment and apoptosis was detected using Annexin V-FITC as
described earlier [25].
Time-lapse microscopy
HCT116 Bax-/- and Bax-/? cells were plated in 35 mm
glass bottom dishes (WillCo-dish, type 3522, WillCo Wells
BV). The cultures were placed in a 37 C chamber equil-
ibrated with humidified air containing 5 % CO2 while
working with video microscopy. At 5 min before obser-
vation, the media was changed to fresh DMEM containing
10 % serum added with TRAIL (100 ng/ml). Time-lapse
microscopy was performed with a Leica AF6000LX
microscope using a 409 objective. The cells were imaged
using differential interference contrast with a classical
halogen lamp as the illumination source. Images were
captured every 7 min and the movies were made out of the
time-lapse series using ImageJ software.
Western blotting
Cells were resuspended in lysis buffer containing 10 mM
HEPES, 300 mM KCl, 5 mM MgCl2, 1 mM EGTA, 1 %
Triton X-100 (v/v), 0.1 % (w/v) sodium dodecyl sulphate
(SDS), pH 7.4, and supplemented with 19 protease inhib-
itors (Roche Diagnostics, Germany). The lysate was cen-
trifuged at 2,0009g, and the protein concentration was
determined by Bradford assay (Bio-Rad). Equal amounts of
protein were subjected to SDS–polyacrylamide gel elec-
trophoresis, and transferred to Hybond-P membranes.
Membranes were blocked with 5 % milk in PBST
(PBS ? 0.05 % Tween 20) and incubated overnight at 4 C
with primary antibodies. Blots were then washed in PBST
and incubated for 1 h with secondary polyclonal antibodies
coupled to horseradish peroxidase. Membranes were then
washed in PBST and developed using chemiluminescence.
Immunocytochemistry and FACS analysis
To visualize the phosphorylation of the myosin light chain
(MLC), HCT116 Bax-/- cells grown on coverslips were
incubated in growth medium, with or without TRAIL for 5
and 24 h. The cells were then fixed in 4 % paraformalde-
hyde, permeabilized and immunostained with an antibody
directed against ppMLC. For the quantification of TRAIL
receptors, Bax-/- cells subjected to different treatments
were stained with anti-TRAIL-R1 and anti-TRAIL-R2
antibodies followed by staining with FITC-conjugated
secondary antibodies and analyzed by FACS.
Cell migration assay
Cell migration was quantified using 24 well cell migration
assay kit (Trevigen) utilizing a modified Boyden chamber
design with polyethylene terephthalate membrane. HCT116
Bax-/- and Bax-/? cells were serum starved overnight.
The following day, cells were re-suspended in serum free
DMEM without or with TRAIL (100 ng/ml), Y-27632
(10 lM) or TRAIL (100 ng/ml) and Y-27632 (10 lM), and
were added into the top inserts of the chamber. DMEM
supplemented with 10 % serum was added into bottom
wells of the chamber followed by incubation for 24 h. The
cells that had migrated were quantified using Calcein-AM
as described by the supplier (Trevigen).
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Results
TRAIL promotes reversible membrane blebbing
and detachment of Bax-/- HTC116 cells and of Bcl-
xL overexpressing SW480 cells
We have compared the effect of TRAIL on Bax-/? and
Bax-/- HCT116 colon cancer cells early after addition of
TRAIL. We observed that *100 % Bax-/? cells dis-
played membrane blebbing and detached from the culture
dish after addition of TRAIL (Fig. 1a, b, c and Movie 1).
These cells were Annexin V positive and displayed a
fragmented nucleus with condensed chromatin, two hall-
marks of apoptosis (Fig. 1d). Bax-/- cells also displayed
membrane blebbing (Fig. 1a, b, d), and *20 % cells were
detached from the culture dish at 5 h TRAIL treatment
(Fig. 1c). To our surprise, however, these blebbing cells
remained Annexin V negative and their nucleus was intact
(Fig. 1d). The Bax-/- cells started blebbing and detach-
ing 1–2 h after TRAIL treatment, with a maximum of cells
blebbing after *10 h (Fig. 1e, f and Movie 2). Thereafter,
blebs began to disappear and the cells were able to
re-attach within the 24 h following TRAIL treatment.
Similar findings were obtained with HCT116 Bax-/? cells
overexpressing Bcl-2 or Bcl-xL (see Supplementary Fig. 1a,
b). Moreover, different colon cancer cells, SW480 cells,
overexpressing Bcl-xL, were found to resist to TRAIL-
induced apoptosis (Supplementary Fig. 2a) and displayed
a similar blebbing phenotype upon exposure to TRAIL
(Supplementary Fig. 2b, c, d). Thus, at least two different
cell types with a defect in the activation of the mitochondrial
intrinsic pathway of apoptosis did not undergo apoptosis
when exposed to TRAIL but showed membrane blebbing,
and a transient loss of adhesion properties.
TRAIL promotes blebbing, detachment and migration
of HCT116 Bax-/- cells by caspase-3 mediated
cleavage of ROCK1
Whereas caspase-8 was equally activated in Bax-/? and
Bax-/- HCT116 cells upon TRAIL treatment (Fig. 2i),
caspases-3 and -7 were not completely processed (p17 and
p12 fragments were not detected) in the absence of Bax
(Fig. 2a), which explained their resistance as previously
reported [26, 33]. One of the caspase-3 substrates is ROCK1
that upon cleavage generates an active truncated kinase,
which is responsible for membrane blebbing and cell
detachment [27, 28]. We analyzed ROCK1 in Bax-/? and
Bax-/- cells and found that the protein was cleaved in both
cell types upon TRAIL treatment (Fig. 2b). Interestingly,
full length ROCK1 was re-expressed in Bax-/- cells that
survived TRAIL treatment (Fig. 2b). In addition, by
immunostaining, we observed a transient increase in the
level of phosphorylation of MLC, a direct substrate of
ROCK1, in TRAIL treated Bax-/- cells (Fig. 2c). MLC
phosphorylation was undetectable in untreated cells or in
TRAIL-treated cells that had re-attached (Fig. 2c). Impor-
tantly, in the presence of ROCK1 inhibitor Y-27632,
membrane blebbing was efficiently blocked in HCT116
Bax-/- cells (Fig. 2d, e). In contrast, this treatment did not
prevent detachment and death of Bax-/? cells (Fig. 2d).
Similar to HCT116 Bax-/- cells, blebbing and detachment
of Bcl-xL overexpressing SW480 cells was significantly
inhibited by the ROCK1 inhibitor Y-27632 (Supplementary
Fig. 2b, c). On the other hand, whereas caspase-8, caspase-
3, PARP and ROCK1 were efficiently cleaved in SW480
control cells, in Bcl-xL overexpressing SW480 cells, only
caspase-8 and ROCK1 were efficiently processed while
caspase-3 was partially processed (Supplementary Fig. 2e).
These observations suggested the involvement of ROCK1
cleavage in the detachment of Bax-/- HCT116 and Bcl-xL
overexpressing SW480 colon cancer cells. Since caspase-3
is known to be responsible for the cleavage of ROCK1 and
cleaved ROCK1 is responsible for blebbing of cells [28,
29], we tested whether down-regulation of caspase-3 would
have an impact on cell blebbing and detachment. We used
RNA interference to down-regulate caspase-3 in HCT116
Bax-/- cells (Fig. 2f). As expected, the ROCK1 protein
was processed less efficiently in caspase-3 siRNA trans-
fected cells than in cells transfected with control siRNA
(Fig. 2i). Consequently membrane blebbing was signifi-
cantly reduced after TRAIL treatment (Fig. 2g, h). In
addition, transient overexpression of a ROCK1 mutant with
constitutive activity [28] (this mutant corresponds to the
caspase 3-cleavage product of ROCK1), was sufficient to
induce membrane blebbing (Supplementary Fig. 3a, b).
Together, these data confirm that caspase-3 mediated
cleavage of ROCK1 is essential and sufficient for the
blebbing of Bax-/- cells.
Fig. 1 TRAIL treatment promotes reversible membrane blebbing in
Bax-/- human colon cancer cells. a HCT116 Bax-/- and Bax-/?
cells were treated with TRAIL (100 ng/ml) and visualized by phase
contrast microscopy. b Western blot showing the status of Bax in
HCT116 Bax-/- and Bax-/? cells. GAPDH is used as the loading
control. c HCT116 Bax-/- and Bax-/? cells were treated with
100 ng/ml of TRAIL for 5 h and the detached cells were collected,
counted and expressed as percentage of the total number of cells in
the well. Results are an average of three independent experiments.
d HCT116 Bax-/- and Bax-/? cells treated with TRAIL (100 ng/
ml) for 5 h were stained with Hoechst and Annexin V-FITC. e Time-
lapse images showing the changes in the morphology of HCT116
Bax-/- cells after treatment with TRAIL (100 ng/ml). Arrowhead
tracks the morphology of a single cell, which starts to bleb after 1 h of
TRAIL treatment and then gradually comes back to normal. f The
number of blebbing cells were quantified from the time-lapse images
taken at the indicated time points. The results are an average of three
independent experiments
c
Apoptosis (2013) 18:324–336 327
123
328 Apoptosis (2013) 18:324–336
123
The blebbing phenotype shown by HCT116 Bax-/-
cells upon TRAIL treatment led us to test whether this
could enhance the migratory activity of these cells. Using
Boyden chambers we compared migration of HCT116
Bax-/- and Bax-/? cells. A significant increase in the
migration of TRAIL treated HCT116 Bax-/- cells com-
pared to untreated cells was observed (Fig. 3). Addition of
the ROCK1 inhibitor Y-27632 suppressed migration of
HCT116 Bax -/- cells in the presence of TRAIL (Fig. 3).
As reported for other cell lines [30, 31] we found that
treatment with Y-27632 alone was sufficient to prevent
migration of HCT116 Bax-/? and Bax-/- cells (Fig. 3)
confirming ROCK1 as a potential target to inhibit cell
migration.
High caspase-3 activation obtained by a combined
treatment with TRAIL and proteasome inhibitor leads
to apoptosis of HCT116 Bax-/- cells
We found that activation of caspase-3 was responsible for
the cleavage of ROCK1 leading to membrane blebbing and
cell detachment. However, caspase-3 was unable to trigger
apoptosis in Bax-/- HCT116 cells. Upon death receptor
stimulation, caspase-3 follows a spatio-temporal activation,
which initiates in the cytosol and leads to the translocation
of at least some of the active fragments into the nucleus to
cleave critical nuclear proteins [32, 33]. Immunostaining of
Bax-/- HCT116 cells revealed that active caspase-3 was
mainly localized at the cell periphery upon engagement of
TRAIL receptor (Fig. 4a). We think that this subcellular
localization may explain why only a limited number of
substrates, including ROCK1, are cleaved by caspase 3
(Fig. 4a). However, this subcellular localization does not
necessarily explain why caspase-3 is unable to undergo full
activation and to trigger apoptosis in these cells.
Bax-/- HCT116 cells express high levels of IAPs such
as XIAP [33], which are known to regulate caspase activity
by ubiquitination and proteasome degradation. We rea-
soned that the small active fragments of caspase-3 (p17 and
p12) produced by caspase-8, possibly at proximity of the
plasma membrane, could be rapidly degraded by the pro-
teasome before they reach their substrates in the nucleus
and elsewhere. In order to test this hypothesis we inhibited
the proteasome in TRAIL-treated cells using the chemical
inhibitor MG-132. Proteasome inhibition has been previ-
ously reported to sensitize cells to TRAIL [34]. We found
that Bax-/- cells treated with TRAIL and MG-132
underwent apoptosis, as did wild type cells in the presence
of TRAIL alone (Figs. 4b, 2a, i). Similarly SW480 colon
cancer cells overexpressing Bcl-xL were sensitized by the
combined treatment of TRAIL and MG-132 (Supplemen-
tary Fig. 2a). Importantly, the use of MG-132 allowed
detection of the short fragment of caspase-3 in HCT116
Bax-/- cells (Figs. 4c, 2a). To strengthen our interpreta-
tion that partial activation of caspase-3 is responsible for
membrane blebbing and cell detachment, we downregu-
lated caspase-3 in HCT116 Bax-/- cells with siRNA
(Fig. 2f). Caspase-3-deficient cells did not detach and were
found to be resistant to the combination of TRAIL and
MG-132 (Figs. 2f, g, h, i, 4b, c).
Acquired resistance of HCT116 Bax-/- cells
to TRAIL
There are numerous reports showing that combining pro-
teasome inhibition with TRAIL is a promising approach for
the treatment of TRAIL resistant cancers [34–39].
Accordingly, we found that cells that had never been
exposed to TRAIL (naı¨ve cells) underwent apoptosis after
exposure to TRAIL and a proteasome inhibitor (Fig. 5a, b).
Interestingly, we observed that Bax-/- cells treated with
TRAIL for 24 h (pretreated cells) became insensitive to a
further co-treatment with TRAIL and proteasome inhibi-
tors MG-132 or bortezomib (Fig. 5a, b). However, sus-
pension of the TRAIL treatment for 48 h (sequentially
treated cells) resensitized cells to the combined treatment
of TRAIL and MG-132 or bortezomib (Fig. 5a, b). More-
over, we found that downregulation of caspase-3 rendered
naı¨ve Bax-/- cells insensitive to TRAIL and MG-132
Fig. 2 TRAIL promotes blebbing and detachment of HCT116
Bax-/- cells by caspase-3 mediated cleavage of ROCK1. a Activa-
tion of caspase-3 and -7 in HCT116 Bax-/- and Bax-/? cells in
response to TRAIL and proteasome inhibitors. Cells were left
untreated or treated with TRAIL (100 ng/ml), TRAIL (100 ng/ml)
and MG-132 (10 lM) or TRAIL (100 ng/ml) and Bortezomib
(25 nM) for 5 h. Protein lysates prepared from these cells were
separated by SDS-PAGE and analyzed for caspase-3 and -7 expres-
sion by Western blotting. Actin was used as the loading control.
b Cell lysates were prepared from HCT116 Bax-/- and Bax-/?
cells left untreated or treated with TRAIL for 5 or 24 h and analyzed
for ROCK1 by Western blotting. The blot is representative of three
independent experiments. c Phosphorylation of MLC in untreated or
TRAIL treated HCT116 Bax-/- cells for 5 and 24 h. d Effect of
ROCK1 inhibitor Y-27632 (10 lM) on TRAIL-induced membrane
blebbing in HCT116 Bax-/? and Bax-/- cells. e Quantification of
TRAIL-mediated membrane blebbing in HCT116 Bax-/- cells in
presence and absence of Y-27632. Mean values ± SEM are shown
for three independent experiments with **p \ 0.01. f Down regula-
tion of caspase-3 by siRNA. HCT116 Bax-/- and Bax-/? cells
were microporated with siRNA for caspase-3 or with a control
siRNA. The cells were harvested after 72 h and the cell lysates were
analyzed for caspase-3 by Western blotting. Caspase-3 deficient
HCT116 Bax-/- cells were treated with TRAIL (100 ng/ml) and
imaged by phase contrast microscopy (g), and the number of blebbing
cells was quantified (h). Mean values ± SEM are shown for three
independent experiments with ***p \ 0.001. i Downregulation of
caspase-3 reduces the processing of ROCK1 in HCT116 Bax-/-
cells. HCT116 Bax-/- and Bax-/?cells transfected with siRNA
targeting caspase-3 or control siRNA were treated with or without
TRAIL, and protein lysates were analyzed for ROCK1, caspase-3,
caspase-8, PARP and actin by Western blotting
c
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co-treatment showing that these drugs work through acti-
vation of caspase-3 (Fig. 4b, c). To understand the mech-
anisms by which pretreated cells exposed to TRAIL
acquired resistance to the combination of TRAIL and a
proteasome inhibitor, we compared the status of caspase-3,
caspase-8, XIAP and the expression of the TRAIL-R1 and
TRAIL-R2 receptors in these cells. We observed that
caspase-8 was significantly less processed in TRAIL-pre-
treated cells (Fig. 6a). Moreover, the amount of XIAP
protein remained constant in TRAIL-pretreated cells,
330 Apoptosis (2013) 18:324–336
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whereas it was decreased in naı¨ve cells treated with TRAIL
(Fig. 6a), possibly as a result of cleavage by caspase-3
[40]. Importantly, expression of both TRAIL-R1 and
TRAIL-R2 receptors was also reduced in pretreated cells
compared to naı¨ve or sequentially treated cells (Fig. 6b).
Interestingly, whereas the level of TRAIL-R2 returned to a
normal value in sequentially treated cells, the level of
TRAIL-R1 remained low (Fig. 6b). Together, these results
suggest that the desensitization of Bax-/- cells to TRAIL
could be in part due to decreased expression of TRAIL-R1
and TRAIL-R2 at the cell surface and that re-sensitization
of these cells to TRAIL after interruption of the treatment
may be due to TRAIL-R2 re-expression.
Discussion
In this paper we show that upon TRAIL treatment, two
different cells lines, HCT116 and SW480 cells, lacking an
efficient intrinsic pathway not only resist apoptosis, but
also display membrane blebbing and an enhanced capa-
bility to migrate. Membrane blebbing and enhanced
migratory activity of these cells lies in the cleavage of
ROCK1 by caspase-3 since inhibition of ROCK1 inhibited
both processes. TRAIL-induced membrane blebbing and
Fig. 3 TRAIL promotes in vitro migration of HCT116 Bax-/- cells.
Migration of HCT116 Bax-/- and Bax-/? cells in response to
TRAIL (100 ng/ml), Y-27632 (10 lM) or TRAIL (100 ng/ml) and
Y-27632 (10 lM) was analyzed using a modified Boyden chamber
assay as described in the ‘‘Materials and methods’’ section. Mean
values ± SD are shown for six independent experiments with
*p \ 0.05
Fig. 4 Potentiation of TRAIL with a proteasome inhibitor. a Immu-
nofluorescence analysis of active caspase-3 in untreated and TRAIL-
treated HCT116 Bax-/- cells for 5 h. b Quantification of apoptosis
using Annexin V staining of control or caspase-3-deficient HCT116
Bax-/- cells treated for 5 h with TRAIL (100 ng/ml) and the
proteosome inhibitor MG-132 (10 lM). Mean values ± SEM are
shown for four independent experiments with **p \ 0.01. c Cell
lysates from these cells were analyzed for PARP, caspase-8, caspase-
3 and actin by Western blotting
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adoption of an amoeboid morphology has previously been
described ([41, 42], A. Ashkenazi, personal communica-
tion). The process of membrane blebbing is not specific for
apoptosis, as this has been observed under many physio-
logical and pathological conditions such as embryonic
development, cell division, cell spreading and metastasis
[43, 44]. Many cancer cell lines such as M2 melanoma or
migrating Walker carcinoma show membrane blebbing
when they move [45]. During metastasis, cancer cells can
either attain a mesenchymal mode of motility utilizing
proteolytic mechanisms or an amoeboid blebbing mode of
motility, or both to bypass tissue barriers before dissemi-
nation into lymphatic or blood vessels [46–48]. The fact
that TRAIL promotes cell blebbing and migration is con-
sistent with previous observations made in vitro [42, 49]
and in vivo [50]. In the latter case, orthotopically trans-
planted human pancreatic ductal adenocarcinoma cells in
the pancreas of severe combined immunodeficiency mice
led to a dramatic increase in metastatic spread upon TRAIL
treatment [50].
HCT116 cells are described as type II cells since they
require the intrinsic pathway to activate executioner
Fig. 5 Acquired resistance to TRAIL. a Naı¨ve cells, pretreated cells
and sequentially treated cells (see ‘‘Materials and methods’’ section)
were treated with TRAIL (100 ng/ml), MG-132 (10 lM), Bortezomib
(25 nM), TRAIL (100 ng/ml) and MG-132 (10 lM) or TRAIL
(100 ng/ml) and bortezomib (25 nM) for 5 h, and imaged. b The
treated cells were harvested and apoptosis was measured by Annexin
V staining. Mean values ± SEM are shown for three independent
experiments with ***p \ 0.0001
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caspases and undergo apoptosis upon engagement of
TRAIL receptors. Activation of the intrinsic pathway,
which leads to the release of Smac/DIABLO from
mitochondria, is required to counteract IAPs and to allow
efficient caspase-3 activation. Accordingly, we observed
that in the absence of a functional intrinsic pathway due to
Fig. 6 TRAIL receptors are downregulated in pretreated HCT116
Bax-/- cells. a Cell lysates prepared from HCT116 Bax-/- cells at
the indicated treatment conditions were analyzed for expression of
caspase-3, caspase-8, XIAP and actin. b Analysis of cell surface
expression of death receptors on HCT116 Bax-/- cells by flow
cytometry. Cells as indicated in the treatment conditions were stained
for anti-TRAIL-R1 or anti-TRAIL-R2 antibodies, counterstained with
FITC conjugated secondary antibodies and analyzed by FACS
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the absence of Bax in HCT116 cells or due to the over-
expression of Bcl-xL in SW480 cells, the level of active
caspase-3 was significantly decreased after TRAIL treat-
ment. This level was, however, sufficient to cleave ROCK1
but insufficient to cleave other key substrates and execute
the cell. This result is in agreement with previous data
showing that activation of caspase-3 is compartmentalized
in many cells types [51, 52] and can be compatible with
cell proliferation, survival and metastasis [53–59]. A wave
of caspase-3 activation has also previously been reported to
diffuse from underneath the plasma membrane to the
nucleus [32, 60]. In Bax-/- HCT116 and Bcl-xL over-
expressing SW480 cells this gradient of activation appears
to be interrupted in the cytosol, due to the lack of Smac/
DIABLO release and the persistence of a high IAP activity.
Previous data have shown that an interaction between the
cleaved form of caspase-3 (p24) and XIAP, one of the IAP
family members, prevents the complete processing of
caspase-3 in HCT116 Bax-/- cells [33]. Moreover, sev-
eral of the human IAPs (XIAP, c-IAP1, and c-IAP2) are
known for their ability to inhibit caspases directly [61, 62].
It was also reported that XIAP acts as a ubiquitin-protein
ligase for caspase-3 [63]. Using constitutively active
mutants of caspase-3, the authors have shown that XIAP
promotes the degradation of the active-form of caspase-3 in
a proteasome-dependent manner. In agreement with these
studies, we found that inhibition of the proteasome, toge-
ther with TRAIL, was accompanied by complete process-
ing of caspase-3 and cell death. Thus inhibition of the
proteasome transformed type II cells into type I cells.
Use of proteasome inhibitors has emerged as a promis-
ing approach for treating a number of cancers. Proteasome
inhibitors enhance TRAIL-induced apoptosis in various
tumor cells including colon cancer cells [35–39, 64].
Interestingly, we observed that a continuous treatment of
Bax-/- cells with TRAIL rendered these cells resistant to
the combination of TRAIL and a proteasome inhibitor.
Previously published data have shown that acquired resis-
tance to TRAIL could occur through c-Cbl-mediated
downregulation of TRAIL receptors TRAIL-R1 and
TRAIL-R2 [65]. In agreement with these findings, we
found a decreased surface expression of TRAIL-R1 and
TRAIL-R2 after exposure of Bax-/- HCT116 cells to
TRAIL for 1 day. Removal of TRAIL from the culture
medium for 2 days allowed these cells to recover expres-
sion of TRAIL-R2. We cannot exclude that in addition to
the decreased surface expression of the receptors, other
mechanisms may be at work to explain desensitization of
the cells to TRAIL.
In conclusion, our observations, although limited to
in vitro studies, are important to consider from a thera-
peutic point of view since they indicate that continuous
TRAIL treatment can promote tumor resistance. Moreover,
they point to the risk of inducing cell migration, and pos-
sibly metastasis, if TRAIL would be used alone to eradi-
cate tumor cells displaying a deficient intrinsic
mitochondrial pathway. In order to prevent cell detachment
and migration, compounds such as ROCK1 inhibitors
could be of great value. Finally our results raise the
intriguing possibility that the immune system may be del-
eterious for the organism when fighting against tumors,
since through expression of TRAIL or other death ligands
of the TNF-a family, it may elicit tumor cell migration and
thereby greatly influence disease outcome. All these
hypotheses will have to be tested in vivo.
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